the 112 th congress made significant changes to the patent system through the leahy - smith america invents act ( aia ) .
both patents and regulatory exclusivities have been the subject of congressional interest in recent years .
the 113 th congress considered additional patent system reforms , including the innovation act .
the innovation act passed the house of representatives in the 113 th congress and has been introduced in the 114 th congress in virtually identical form .
starting with the orphan drug act , congress has also developed a new form of intellectual property right in order to promote the marketing of new drugs .
patents , which are administered by the u.s. patent and trademark office ( uspto ) , allow for a uniform 20-year term of protection for a variety of inventions .
that unenacted legislation would have effectively allowed brand - name pharmaceutical firms , in certain circumstances , to exchange their patents for a 15-year period of regulatory exclusivity .
regulatory exclusivities apply to drugs and biologic medicines regulated by the food and drug administration ( fda ) .
the biologics price competition and innovation act of 2009 created a 12-year regulatory exclusivity , and under the generating antibiotics incentives now ( gain ) act a "qualified infectious disease product" that consists of a new chemical entity enjoys an exclusivity period of 10 years .